CN101812072A - Method for preparing anti-platelet aggregation compounds - Google Patents
Method for preparing anti-platelet aggregation compounds Download PDFInfo
- Publication number
- CN101812072A CN101812072A CN 201010182374 CN201010182374A CN101812072A CN 101812072 A CN101812072 A CN 101812072A CN 201010182374 CN201010182374 CN 201010182374 CN 201010182374 A CN201010182374 A CN 201010182374A CN 101812072 A CN101812072 A CN 101812072A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- preparation
- reaction
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical chemistry, in particular to a new method for preparing anti-platelet aggregation compounds with a structure shown in a general formula I. In the preparation route, cheap and readily available initiative materials, namely methyl alpha-bromo-2-chlorophenylacetate and thiophene-2-ethylamine, replace clopidogrel in the conventional document. Concretely, the methyl alpha-bromo-2-chlorophenylacetate is reacted with the thiophene-2-ethylamine, replace clopidogrel under the catalysis of an acid-catcher to generate an intermediate II; the intermediate II is reacted with hydrazine hydrate, acetone or 3-pentanone to generate an intermediate III; and the intermediate III undergoes cyclization to generate the compounds in the formula I. The method has the advantages of mild reaction conditions, simple and safe operating process, and easy industrial production; and the product has stable quality, high purity and high yield; compared with that of the synthetic process provided by the conventional document, the production cost is greatly reduced; and in the formula I, R refers to methyl or ethyl.
Description
Technical field
The invention belongs to technical field of pharmaceutical chemistry, be specifically related to the synthetic method of a class anti-platelet aggregation compounds, relate in particular to the industrial process of this class anti-platelet aggregation compounds.
Background technology
Thrombosis can cause the heart, brain, pulmonary circulation illness such as Acute Myocardial Infarction, apoplexy, pulmonary infarction, is threatening human beings'health and life, also is common complication and the inaccessible again factor of intervention property postangioplasty in the surgical operation.Though the thromboembolism treatment of carrying out in recent years, interventional therapy even operative treatment make acute myocardial infarction and treatment of cerebral obtain the progress that attracts people's attention, patient's salvage success rate improves greatly, quality of life has also had tangible improvement, but the cardiovascular and cerebrovascular disease disability rate is after all up to 30%.Therefore the drug development of prevention and treatment cardiovascular and cerebrovascular disease becomes the focus of paying close attention in recent years and studying.Cause thrombotic factor a lot, as thrombocyte stagnate in the lip-deep adhesion of vessel wall and the gathering, the blood flow stasis of blood of damage, the activation of thrombin impels the formation of zymoplasm, antiplasmin activity is low inferior, can both impel thrombosis.Thrombocyte is thrombotic essential material in these factors, thus suppress hematoblastic accumulate in the prevention of thrombus disease and treat in play an important role.Adenosine diphosphate (ADP) (ADP) is the important agonist that platelet activation, buildup effect amplify, and suppressing the thrombocyte effect by the blocking-up adp receptor has become the important means that stops pathologic thrombosis (coronary heart disease, cerebro-vascular diseases, pulmonary infarction, thrombophlebitis etc.) and myocardial infarction, unstable angina pectoris, peripheral vascular disease, congestive heart failure etc.
Clopidogrel is the adp receptor inhibitor class antiplatelet drug of a present clinical line, because it is the extremely weak oily matter of alkalescence, needs and strong acid ability salify.Its salt is met the moisture instability, and free alkali is separated out, and purifying has certain difficulty.And because the strongly-acid of its salt also can be subjected to certain restriction aspect preparation.Patent ZL200510016205.X provides a kind of new A DP receptor-blocking agent class antiplatelet formula I compound, when having excellent activity, has more superior physico-chemical property compared to clopidogrel.Because its free alkali itself is solid, the stability of its salt is also better, is easy to purifying and preparation.
Chemical name:
(S)-and α, α-[2-chloro-phenyl--2-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also)]-N '-[(dimethyl) methene base] acethydrazide (when R is a methyl);
(S)-and α, α-[2-chloro-phenyl--2-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also)]-N '-[(diethyl) methene base] acethydrazide (when R is an ethyl).
Chemical structure:
Wherein R is methyl or ethyl.
The synthetic method of this compound of putting down in writing among the patent ZL200510016205.X is as follows:
In the reaction flask that stirring, condenser, thermometer are housed, add clopidogrel 38g, dehydrated alcohol 30mL, stir down slowly heating, make the reaction raw materials dissolving, add 45.6g hydrazine hydrate (80%), continue to be heated to backflow, insulation reaction 4 hours, (the flaggy demonstration reacts completely).Solvent is to the greatest extent steamed in decompression then, steams and finishes, and adds 50mL distilled water and 30mL methylene dichloride in resistates, fully stirs, and tells organic layer, and water layer merges organic layer with 3 * 30mL dichloromethane extraction, uses the anhydrous sodium sulphate thorough drying.Methylene dichloride is to the greatest extent steamed in decompression, white solid 23.4g (HPLC:97.16), m.p.139.0～139.3 ℃.
In the reaction flask that stirring, condenser, thermometer are housed, add hydrazides thing 4g, anhydrous methanol 40mL, start stirring, heating makes its dissolving.Continue to be heated to 40 ℃, drip 0.79g acetone, finish, insulation reaction 3 hours (the flaggy demonstration reacts completely).Stopped reaction, cooling has solid to generate.Filter, anhydrous methanol 3 * 2mL washing, drying gets solid product (HPLC:99.8%).M.p.169.1～170.8 ℃, Rf=0.3[single-point, developping agent: sherwood oil (60-90 ℃): ethyl acetate=1: 1].
There is following shortcoming in the technical program:
1. need to buy clopidogrel be raw material to this synthetic method, and cost is higher, is not suitable for industrialized production.
2. operation steps is comparatively loaded down with trivial details, repeatedly reaction solution is carried out aftertreatment, if be used for industrialized production, not only wasting a large amount of reagent increases cost, does not also meet environmental requirement.
3. use a large amount of hydrazine hydrates, be unfavorable for labour protection.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of method of preparation I compound of suitable industrialized production is provided, its purpose is to overcome the existing high shortcoming of synthetic method cost of material, when guaranteeing quality product, select the cheap raw material that is easy to get for use, thereby reduce production costs, be fit to large-scale industrialization production.
Technical scheme provided by the invention is as follows:
2-(2-chloro-phenyl-)-2-bromo-methyl acetate and 2-(thiophene-2-yl) ethamine reacts under the catalysis of acid binding agent, generates intermediate II.Intermediate II and hydrazine hydrate, acetone or propione reaction generate intermediate III.Intermediate III cyclization reaction production I compound.
Wherein R is methyl or ethyl.
With dissolvings such as 2-(2-chloro-phenyl-)-2-bromo-methyl acetate methylene dichloride, trichloromethane, toluene, dioxane.Add acid binding agents such as triethylamine, pyridine, salt of wormwood, yellow soda ash, sodium bicarbonate, saleratus, sodium hydroxide or potassium hydroxide.Add 2-(thiophene-2-yl) ethamine stirring reaction again, generate intermediate II.With the solution of intermediate II, be warming up to 50～60 ℃ of mixed solutions that add hydrazine hydrate and acetone or propione, reaction makes intermediate III; Intermediate III is dissolved in organic acid or mineral acid, with formaldehyde the Pictet-Spengler reaction takes place, and makes formula I compound.
Wherein the concentration of hydrazine hydrate is 60-90%; The mol ratio of intermediate II, hydrazine hydrate and acetone or propione is 1: (1-1.2): (1-1.2).Organic acid that Pictet-Spengler reaction is used or mineral acid are wherein a kind of of formic acid, acetate, hydrochloric acid, sulfuric acid; Temperature of reaction is 30～100 ℃; The mol ratio of compound III, acid and formaldehyde is 1: (1-4): (1-2).
The present invention compared with prior art, its remarkable advantage is:
1. replace clopidogrel with starting raw material 2-cheap and easy to get (2-chloro-phenyl-)-2-bromo-methyl acetate and 2-(thiophene-2-yl) ethamine, greatly reduce production cost.
2. reaction conditions gentleness, simple and safe operation process is easy to realize suitability for industrialized production.Reaction times is short, need not heat, less demanding to equipment, and it is low to consume energy.Saved the energy, facility investment and running cost, effects of energy saving and emission reduction is obvious, meets the requirement of low-carbon economy.
3. significantly reduce the hydrazine hydrate usage quantity, be beneficial to labour protection.
4. constant product quality, the purity height, the productive rate height can reach the requirement of industrial amplification production.
Embodiment
The present invention can realize by following concrete technology:
Reference example: 2-(2-chloro-phenyl-)-2-[2-(thiophene-2-yl) ethamine] methyl acetate (II) synthetic
In the 250mL reaction flask, add 2-(2-chloro-phenyl-)-2-bromo-methyl acetate 26.4g (0.1mol) and 100mL methylene dichloride, start stirring, molten clear back adds 27.6g (0.2mol) Anhydrous potassium carbonate, adds 2-(thiophene-2-yl) ethamine 12.7g (0.1mol) in batches.After finishing, be warming up to back flow reaction 3 hours (the flaggy demonstration reacts completely).Stopped reaction filters.With small portion filtrate evaporate to dryness, get white solid product (HPLC:98.4%).
1H?NMR(DMSO-d
6，400MHz)δ：2.997～3.068(m，1H)，3.107～3.177(m，1H)，3.253～3.339(m，2H)，3.725(s，3H)，5.588(s，1H)，6.903～6.909(d，1H)，6.941～6.962(m，1H)，7.364～7.379(q，1H)，7.463～7.532(m，2H)，7.599～7.622(q，1H)，7.756～7.779(m，1H)，10.456(bro，1H)。
Embodiment 1: intermediate III-1 synthetic
With the solution of gained intermediate II of last step, be warming up to 50 ℃, stir the mixed solution that adds 60% hydrazine hydrate 8.34g (0.1mol) and acetone 5.81g (0.1mol) down, in 50 ℃ of reaction 1h (the flaggy demonstration reacts completely).Stopped reaction, cooling has solid to generate.Filter, drying gets solid product 30.3g (HPLC:99.8%), yield 86.7%.The Rf=0.41[single-point, developping agent: ethyl acetate: sherwood oil (60-90 ℃)=1: 1].
Embodiment 2:Synthesizing of intermediate III-2
With the solution of gained intermediate II of last step, be warming up to 60 ℃, stir the mixed solution that adds 90% hydrazine hydrate 6.67g (0.12mol) and propione 10.3g (0.12mol) down, in 60 ℃ of reaction 0.5h (the flaggy demonstration reacts completely).Stopped reaction, cooling has solid to generate.Filter, drying gets solid product 33.4g (HPLC:99.0%), yield 87.4%.The Rf=0.45[single-point, developping agent: ethyl acetate: sherwood oil (60-90 ℃)=1: 1].
Embodiment 3:(S)-and α, α-[2-chloro-phenyl--2-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also)]-N '-[(dimethyl) methene base] acethydrazide
In the 250mL reaction flask that stirring, condenser, thermometer are housed, add 3.5g (0.01mol) intermediate III-1, add 15% formic acid solution 10mL (0.04mol), stir adding 0.6g (0.02mol) formaldehyde down.Be warming up to 50 ℃ and continue reaction 0.5h (the flaggy demonstration reacts completely).Stopped reaction, with 3 * 10mL dichloromethane extraction, anhydrous sodium sulfate drying, solvent is to the greatest extent steamed in decompression, gets solid product 3.24g (HPLC:99.3%), yield 89.4%.M.p.169.0-170.6 ℃, Rf=0.37[single-point, developping agent: ethyl acetate: sherwood oil (60-90 ℃)=1: 1].
Embodiment 4:(S)-and α, α-[2-chloro-phenyl--2-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also)]-N '-[(diethyl) methene base] acethydrazide
In the 250mL reaction flask that stirring, condenser, thermometer are housed, add 3.8g (0.01mol) intermediate III-2, add 15% hydrochloric acid soln 8mL (0.03mol), stir adding 0.5g (0.015mol) formaldehyde down.Be warming up to 70 ℃ and continue reaction 0.5h (the flaggy demonstration reacts completely).Stopped reaction, with 3 * 10mL dichloromethane extraction, anhydrous sodium sulfate drying, solvent is to the greatest extent steamed in decompression, gets solid product 3.38g (HPLC:99.0%), yield 86.6%.M.p.168.5-170.1 ℃, Rf=0.40[single-point, developping agent: ethyl acetate: sherwood oil (60-90 ℃)=1: 1].
Claims (8)
1. preparation method suc as formula the I compound is characterized in that technical process and reaction conditions carry out in the following manner:
Wherein R is methyl or ethyl
Intermediate II and hydrazine hydrate, acetone or propione reaction generate intermediate III.Intermediate III and formaldehyde cyclization reaction production I compound.
2. the preparation method of a formula I compound as claimed in claim 1 is characterized in that:
(1) with the solution of intermediate II, be warming up to 50～60 ℃ of mixed solutions that add hydrazine hydrate and acetone or propione, reaction makes intermediate III;
(2) intermediate III is dissolved in organic acid or mineral acid, with formaldehyde the Pictet-Spengler reaction takes place, and makes formula I compound.
3. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: the solvent of described flow process (1) is that methylene dichloride, trichloromethane, toluene, dioxane are wherein a kind of.
4. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: the concentration of the hydrazine hydrate of described flow process (1) is 60-90%.
5. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: intermediate II, hydrazine hydrate and the acetone of described flow process (1) or the mol ratio of propione are 1: (1-1.2): (1-1.2).
6. the preparation method of a formula I compound as claimed in claim 2 is characterized in that: the organic acid of described flow process (2) or mineral acid are wherein a kind of of formic acid, acetate, hydrochloric acid, sulfuric acid.
7. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: the temperature of reaction of described flow process (2) is 30～100 ℃.
8. the preparation method of a formula I compound as claimed in claim 2, it is characterized in that: the mol ratio of compound III, acid and the formaldehyde of described flow process (2) is 1: (1-4): (1-2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101823741A CN101812072B (en) | 2010-05-27 | 2010-05-27 | Method for preparing anti-platelet aggregation compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101823741A CN101812072B (en) | 2010-05-27 | 2010-05-27 | Method for preparing anti-platelet aggregation compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101812072A true CN101812072A (en) | 2010-08-25 |
| CN101812072B CN101812072B (en) | 2012-07-04 |
Family
ID=42619450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101823741A Active CN101812072B (en) | 2010-05-27 | 2010-05-27 | Method for preparing anti-platelet aggregation compounds |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101812072B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102796093A (en) * | 2012-08-23 | 2012-11-28 | 天津药物研究院 | Thiomorpholine-containing pyrrole derivatives and their preparation method and use |
| CN103665042A (en) * | 2012-09-21 | 2014-03-26 | 北京普禄德医药科技有限公司 | Optically active 2-hydroxyltetrahydrothienopyridine derivative as well as preparation method and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1683373A (en) * | 2005-02-23 | 2005-10-19 | 天津药物研究院 | Thiophenopyridine substituted acetyl hyarazine derivative |
| CN101260112A (en) * | 2008-04-11 | 2008-09-10 | 天津药物研究院 | Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof |
-
2010
- 2010-05-27 CN CN2010101823741A patent/CN101812072B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1683373A (en) * | 2005-02-23 | 2005-10-19 | 天津药物研究院 | Thiophenopyridine substituted acetyl hyarazine derivative |
| CN101260112A (en) * | 2008-04-11 | 2008-09-10 | 天津药物研究院 | Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《Chinese Chemical Letters》 20081231 Die Cheng et al Synthesis and activity evaluation of some novel derivatives of 4,5,6,7-tetrahydrothieno [3,2-c]-pyridine 689-692 1-8 第19卷, 2 * |
| 《中国药学杂志》 20091130 成碟等 含有取代哌嗪及哌啶结构的噻吩并吡啶类化合物的合成及活性研究 1752-1754 1-8 第44卷, 第22期 2 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102796093A (en) * | 2012-08-23 | 2012-11-28 | 天津药物研究院 | Thiomorpholine-containing pyrrole derivatives and their preparation method and use |
| CN102796093B (en) * | 2012-08-23 | 2015-06-24 | 天津药物研究院 | Thiomorpholine-containing pyrrole derivatives and their preparation method and use |
| CN103665042A (en) * | 2012-09-21 | 2014-03-26 | 北京普禄德医药科技有限公司 | Optically active 2-hydroxyltetrahydrothienopyridine derivative as well as preparation method and use thereof |
| CN103665042B (en) * | 2012-09-21 | 2016-03-16 | 北京普禄德医药科技有限公司 | Optically active 2-hydroxy tetrahydro thienopyridine derivative and its production and use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101812072B (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5395908B2 (en) | Process for producing 4- (1-hydroxy-1-methylethyl) -2-propylimidazole-5-carboxylic acid ester | |
| JP7268280B2 (en) | Manufacturing process of amantadine-based nitrate derivatives | |
| CN106632244A (en) | A novel synthetic method for preparing an anticancer medicine Niraparib | |
| CN101812072B (en) | Method for preparing anti-platelet aggregation compounds | |
| CN103420902A (en) | Preparation method of 2-chloro-4-iodo-5-methylpyridine | |
| CN101693694A (en) | Preparation method of glyoxaline formic ether and derivative thereof | |
| CN103539773A (en) | Method for preparing ticagrelor key intermediate | |
| CN109575017A (en) | A kind of preparation method of Olprinone HCl compound | |
| CN104370935B (en) | A kind of preparation method of bisulfate clopidogrel | |
| CN106946880B (en) | A method of preparing Rui Boxini intermediate | |
| CN103755659B (en) | 6-cinnamon acyl-2H-benzo [b] [1, 4] oxazine-3 (4H)-ketone compound and application thereof | |
| CN101781311B (en) | Novel preparation method of platelet aggregation inhibition compound | |
| CN106268940A (en) | Xylan base carbon-based solid acid and the method being catalyzed and synthesized benzodiphenylene oxide compounds by it | |
| CN103588758A (en) | Synthesis and preparation of nitroimidazole derivative containing 1,4-benzdioxan skeleton and application of nitroimidazole derivative in anticancer drugs | |
| CN102372687A (en) | Production method for spirodiclofen | |
| CN101812073B (en) | Method for preparing acethydrazide derivatives | |
| CN103724325B (en) | Prepare the method for sulfinyl-1-hydrogen-benzimidizole derivatives | |
| CN105732521A (en) | Preparation method of dihydrogen quinazolinone derivative | |
| CN102766163B (en) | Synthesis method of phosphate monoester of vitamin B1 | |
| CN109574938B (en) | Method for synthesizing rosuvastatin sodium | |
| CN106478518A (en) | A kind of preparation method of heptenoic acid ring pentyl ester derivant | |
| CN101792434B (en) | Preparation method of tetra-acylated puerarin | |
| CN101824010B (en) | Method for synthesizing 4-aryl-4,5-dihydrofuran | |
| CN111116493A (en) | Method for preparing Apabetalone, intermediate and preparation method of intermediate | |
| CN106749138B (en) | A kind of preparation method of sulfuric acid Walla pa sand intermediate aldehydes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 300301 No. 306, Huiren Road, Binhai Science Park, Binhai high tech Zone, Binhai New Area, Tianjin Patentee after: Tianjin Institute of Pharmaceutical Research Co.,Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220406 Address after: 300301 No. 29, Huixin Road, Binhai Science Park, Binhai high tech Zone, Tianjin Binhai New Area, Tianjin Patentee after: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH PHARMACEUTICAL RESPONSIBLE CO.,LTD. Address before: 300301 No. 306, Huiren Road, Binhai Science Park, Binhai high tech Zone, Binhai New Area, Tianjin Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd. |